Skip to content

MBX Biosciences, Inc. MBX Short- term Investments

Short- term Investments at other companies

Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
Roivant Sciences logo
Roivant SciencesROIV
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%
Enterprise value$2.26B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s short- term investments?
MBX Biosciences, Inc. (MBX) reported short- term investments of $394.76M in Q1 2026.
How has MBX Biosciences, Inc.'s short- term investments changed year-over-year?
MBX Biosciences, Inc.'s short- term investments increased by 87.2% year-over-year, from $210.88M to $394.76M.
What is the long-term trend for MBX Biosciences, Inc.'s short- term investments?
Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s short- term investments has grown at a 143.9% compound annual growth rate (CAGR), from $50.15M to $298.42M.